CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
CONCLUSION: Atezolizumab plus cabozantinib after disease progression following anti-PD-L1/PD-1 immunotherapy and platinum-containing chemotherapy for metastatic NSCLC did not improve OS compared with docetaxel. Safety was consistent with known profiles of these agents.PMID:38552197 | DOI:10.1200/JCO.23.02166 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Joel Neal Nick Pavlakis Sang-We Kim Yasushi Goto Sun Min Lim Giannis Mountzios Elena Fountzilas Anastasia Mochalova Daniel C Christoph Alessandra Bearz Xavier Quantin Ramon Palmero Vladan Antic Elaine Chun Tirupathi Rao Edubilli Ya-Chen Lin Mahrukh Huseni Source Type: research
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
CONCLUSION: Anlotinib plus docetaxel offers a viable therapeutic alternative for patients with advanced NSCLC who failed first-line platinum-based treatments.PMID:38552544 | DOI:10.1016/j.lungcan.2024.107538 (Source: Cancer Control)
Source: Cancer Control - March 29, 2024 Category: Cancer & Oncology Authors: Xingxiang Pu Zemin Xiao Jia Li Zhijun Wu Zhongxia Ma Jie Weng Maoliang Xiao Yanhua Chen Yongqing Cao Peiguo Cao Qianzhi Wang Yan Xu Kang Li Bolin Chen Fang Xu Liyu Liu Yi Kong Hui Zhang Huaxin Duan Lin Wu Source Type: research
Cytotoxicity and Apoptosis Studies of Brucein D against T24 Bladder Cancer Cells
CONCLUSION: BrD has shown a cytotoxic effect against T24 bladder cancer cells. Hence, it is a promising natural compound for the management of bladder cancer by induction of apoptosis through activation of the intrinsic pathway, with low toxicity to normal cells.PMID:38546074 | DOI:10.31557/APJCP.2024.25.3.921 (Source: Cancer Control)
Source: Cancer Control - March 28, 2024 Category: Cancer & Oncology Authors: Pandu Ishaq Nandana Haerani Rasyid Prihantono Prihantono Ika Yustisia Lukman Hakim Agussalim Bukhari Eka Sunarwidhi Prasedya Source Type: research
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.PMID:38538963 | DOI:10.1007/s10147-024-02501-7 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Shoji Kimura Keisuke Shigeta Shingo Tamura Keita Uchino Takahiro Kimura Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito E Source Type: research
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study
CONCLUSION: Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.PMID:38538968 | DOI:10.1007/s12094-024-03440-5 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Alejandro Falc ón González Josefina Cruz Jurado Elisenda Llabr és Valenti Roc ío Urbano Cubero Maria Carmen Álamo de la Gala Mar ía Antonia Martínez Guisado Roc ío Álvarez Ambite Carlos Jos é Rodríguez González Marta Am érigo Góngora Lourdes Source Type: research
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study
CONCLUSION: Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.PMID:38538968 | DOI:10.1007/s12094-024-03440-5 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Alejandro Falc ón González Josefina Cruz Jurado Elisenda Llabr és Valenti Roc ío Urbano Cubero Maria Carmen Álamo de la Gala Mar ía Antonia Martínez Guisado Roc ío Álvarez Ambite Carlos Jos é Rodríguez González Marta Am érigo Góngora Lourdes Source Type: research
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.PMID:38538963 | DOI:10.1007/s10147-024-02501-7 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Shoji Kimura Keisuke Shigeta Shingo Tamura Keita Uchino Takahiro Kimura Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito E Source Type: research
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.PMID:38538963 | DOI:10.1007/s10147-024-02501-7 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Shoji Kimura Keisuke Shigeta Shingo Tamura Keita Uchino Takahiro Kimura Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito E Source Type: research
Cytotoxicity and Apoptosis Studies of Brucein D against T24 Bladder Cancer Cells
CONCLUSION: BrD has shown a cytotoxic effect against T24 bladder cancer cells. Hence, it is a promising natural compound for the management of bladder cancer by induction of apoptosis through activation of the intrinsic pathway, with low toxicity to normal cells.PMID:38546074 | DOI:10.31557/APJCP.2024.25.3.921 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - March 28, 2024 Category: Cancer & Oncology Authors: Pandu Ishaq Nandana Haerani Rasyid Prihantono Prihantono Ika Yustisia Lukman Hakim Agussalim Bukhari Eka Sunarwidhi Prasedya Source Type: research
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.PMID:38538963 | DOI:10.1007/s10147-024-02501-7 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Shoji Kimura Keisuke Shigeta Shingo Tamura Keita Uchino Takahiro Kimura Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito E Source Type: research
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study
CONCLUSION: Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.PMID:38538968 | DOI:10.1007/s12094-024-03440-5 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Alejandro Falc ón González Josefina Cruz Jurado Elisenda Llabr és Valenti Roc ío Urbano Cubero Maria Carmen Álamo de la Gala Mar ía Antonia Martínez Guisado Roc ío Álvarez Ambite Carlos Jos é Rodríguez González Marta Am érigo Góngora Lourdes Source Type: research
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.PMID:38538963 | DOI:10.1007/s10147-024-02501-7 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Shoji Kimura Keisuke Shigeta Shingo Tamura Keita Uchino Takahiro Kimura Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito E Source Type: research
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.PMID:38538963 | DOI:10.1007/s10147-024-02501-7 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Shoji Kimura Keisuke Shigeta Shingo Tamura Keita Uchino Takahiro Kimura Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito E Source Type: research
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study
CONCLUSION: Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.PMID:38538968 | DOI:10.1007/s12094-024-03440-5 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Alejandro Falc ón González Josefina Cruz Jurado Elisenda Llabr és Valenti Roc ío Urbano Cubero Maria Carmen Álamo de la Gala Mar ía Antonia Martínez Guisado Roc ío Álvarez Ambite Carlos Jos é Rodríguez González Marta Am érigo Góngora Lourdes Source Type: research
Cytotoxicity and Apoptosis Studies of Brucein D against T24 Bladder Cancer Cells
CONCLUSION: BrD has shown a cytotoxic effect against T24 bladder cancer cells. Hence, it is a promising natural compound for the management of bladder cancer by induction of apoptosis through activation of the intrinsic pathway, with low toxicity to normal cells.PMID:38546074 | DOI:10.31557/APJCP.2024.25.3.921 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - March 28, 2024 Category: Cancer & Oncology Authors: Pandu Ishaq Nandana Haerani Rasyid Prihantono Prihantono Ika Yustisia Lukman Hakim Agussalim Bukhari Eka Sunarwidhi Prasedya Source Type: research
